<DOC>
	<DOCNO>NCT00003465</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness temozolomide treat patient anaplastic oligodendroglioma .</brief_summary>
	<brief_title>Temozolomide Treating Patients With Anaplastic Oligodendroglioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine activity temozolomide patient newly diagnose , progressive , recurrent anaplastic oligodendroglioma . II . Determine toxicity drug patient population . OUTLINE : Patients stratify accord disease characteristic ( newly diagnose anaplastic oligodendroglioma versus recurrent anaplastic oligodendroglioma ) . Patients receive oral temozolomide daily day 1-5 . Treatment repeat every 28 day . Patients progressive recurrent disease ( baseline ) continue treatment absence disease progression unacceptable toxicity . Patients newly diagnose disease continue treatment maximum 4 course radiotherapy absence disease progression unacceptable toxicity . Patients respond disease may receive additional 6 course completion radiotherapy . ( Radiotherapy part study treatment . ) Patients follow every 8 week 2 year . PROJECTED ACCRUAL : A maximum 60 patient ( 30 per stratum ) accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm supratentorial anaplastic oligodendroglioma anaplastic oligoastrocytoma require immediate radiotherapy Newly diagnose , progressive , recurrent disease Bidimensionally measurable disease At least 1.5 cm2 MRI PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : More 12 week Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT/SGPT le 2.5 time ULN Alkaline phosphatase less 2 time ULN Renal : BUN le 1.5 time ULN Creatinine less 1.5 time ULN Other : Neurologically stable No nonmalignant systemic disease No acute infection treat intravenous antibiotic No frequent vomit No medical condition ( e.g. , partial bowel obstruction ) would interfere oral medication intake No prior concurrent malignancy except surgically cure carcinoma situ cervix basal cell squamous cell carcinoma skin No AIDSrelated illness HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No 1 prior biologic therapy No concurrent biologic therapy No concurrent growth factor ( e.g. , epoetin alfa ) Chemotherapy : No 1 prior chemotherapy regimen No concurrent chemotherapy Endocrine therapy : Must stable dose steroid least 1 week prior study Concurrent steroid allow Radiotherapy : See Disease Characteristics No concurrent radiotherapy Surgery : At least 2 week since prior surgical resection ( newly diagnose patient must enrol within 28 day surgery biopsy ) Recovered prior major surgery Other : No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
</DOC>